Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2019) [Effective from January 1, 2019]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2019)
[Effective from January 1, 2019]
For more details click here

ICV 2018: 95.39
Index Copernicus ICI Journals Master List 2017 - IJCMAS--ICV 2018: 95.39
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2017: 100.00
NAAS RATING 2018: 5.38

Int.J.Curr.Microbiol.App.Sci.2016.5(11): 515-522
DOI: http://dx.doi.org/10.20546/ijcmas.2016.511.060


Prevalence of ESBL and MBL producing Acinetobacter Isolates in Clinical Specimens in Tertiary Care Hospital, Assam, India 
Harekrishna Nath* and Dipa Barkataki
Department of Microbiology, Gauhati Medical College and Hospital, Assam, India
*Corresponding author
Abstract:

Outbreaks of infection caused by strains of A. baumannii resistant to multiple antibiotic classes, including carbapenems, are a serious concern in many specialized hospital units, including intensive care units (ICUs) Clinical isolates of Acinetobacter species initially retained at least partial susceptibility against the 3rd and 4th generations viz cephalosporins, fluoroquinolones, semisynthetic aminoglycosides, carbapenems and 100% susceptibility to imipenem but the clinical utility of this class of antimicrobial is increasingly being jeopardized by the emergence of both enzymatic and membrane-based mechanisms of resistance. The increase in the number of MBLs in A. baumannii is an ominous development in the global emergence of resistance to β-lactams. Keeping this things mind study was carried out to know the prevalence of ESBL & MBL producing Acinetobacter isolates in tertiary care hospital. A total of 31 no’s Acinetobacter isolation was done from clinical specimens from different medical wards, surgical wards and ICU department of GMCH for a period of one year from August 2014--July 2015. Isolated Acinetobacter spp were tested for ESBL (Extended spectrum Beta Lactamase) by double disc synergy and MBL (Matelo Beta Lactamese) by imipenem and Imepenem+EDTA E-test method. Out of the total of 31 Acinetobacter isolates, MDR isolates found to be 13(41.94%) of which A.baumannii 12(92.30%) and Acinetobacter lwoffii 1(7.69%). MDR Acinetobacter were sensitive to Polymixin B (100%) followed by Tigecycline, colistin (92.85%). Out of the total of 31 Acinetobacter isolates, 32.25 % isolates are ESBL producer and 38.7% of isolates were MBL producer and all MBL producers were isolated from ICU. Maximum MDR, ESBL and MBL isolation rates were seen from tracheal aspirates. In our study 32.25 % isolates and 38.7%of isolates were ESBL and MBL producer respectively and all MBL producers were isolated from ICU. Therefore early detection is necessary to screen and confirm beta lactamase mediated resistant strains to avoid treatment failure and prevent the spread of MDR.


Keywords: MDR A.baumannii, ESBL producer, MBL producer, Matelo Beta Lactamese
Download this article as Download

How to cite this article:

Harekrishna Nath and Dipa Barkataki. 2016. Prevalence of ESBL and MBL producing Acinetobacter Isolates in Clinical Specimens in Tertiary Care Hospital, Assam, India.Int.J.Curr.Microbiol.App.Sci. 5(11): 515-522. doi: http://dx.doi.org/10.20546/ijcmas.2016.511.060